Could an Anti-Inflammatory pill slow Parkinson's?
NCT ID NCT07157735
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether dapansutrile, a drug that targets inflammation, is safe and can reduce brain and body inflammation in people with early Parkinson's disease. 36 participants will take either the drug or a placebo daily for 6 months, with brain scans and spinal taps to measure effects. The goal is to see if calming inflammation might help modify the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
dapansutrile
What this could lead to
If it works, this could point toward a new way to slow Parkinson's progression by targeting inflammation.
What could go wrong
This is a small early-phase trial with only 36 people, so results may not apply widely. The drug may not reduce inflammation or improve symptoms, and side effects are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
John Van Geest Centre for Brain Repair
RECRUITINGCambridge, CB2 0PY, United Kingdom